An update on levosimendan in acute cardiac care: applications and recommendations for optimal efficacy and safety

References

• Heringlake M, Wernerus M, Grünefeld J, et al. The metabolic and renal effects of adrenaline and milrinone in patients with myocardial dysfunction after coronary artery bypass grafting. Crit Care. 2007;11(2):R51.
   PubMed Web of Science ®Google Scholar
• Tacon CL, McCaffrey J, Delaney A. Dobutamine for patients with severe heart failure: a systematic review and meta-analysis of randomised controlled trials. Intensive Care Med. 2012;38(3):359–367.
   PubMed Web of Science ®Google Scholar
• Léopold V, Gayat E, Pirracchio R, et al. Epinephrine and short-term survival in cardiogenic shock: an individual data meta-analysis of 2583 patients. Intensive Care Med. 2018;44(6):847–856.
   PubMed Web of Science ®Google Scholar
• Mebazaa A, Parissis J, Porcher R, et al. Short-term survival by treatment among patients hospitalized with acute heart failure: the global ALARM-HF registry using propensity scoring methods. Intensive Care Med. 2011;37(2):290–301.
   PubMed Web of Science ®Google Scholar
• Uhlig K, Efremov L, Tongers J, et al. Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome. Cochrane Database Syst Rev. 2020;11:CD009669.
   PubMedGoogle Scholar
• Cuffe MS, Califf RM, Kirkwood FAJ, et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure a randomized controlled trial. JAMA. 2002;287(12):1541–1547.
   PubMed Web of Science ®Google Scholar
• Metra M, Eichhorn E, Abraham WT, et al. Effects of low-dose oral enoximone administration on mortality, morbidity, and exercise capacity in patients with advanced heart failure: the randomized, double-blind, placebo-controlled, parallel group ESSENTIAL trials. Eur Heart J. 2009;30(24):3015–3026.
   PubMed Web of Science ®Google Scholar
• Ren YS, Li LF, Peng T, et al. The effect of milrinone on mortality in adult patients who underwent CABG surgery: a systematic review of randomized clinical trials with a meta-analysis and trial sequential analysis. BMC Cardiovasc Disord. 2020;20(1):328.
   PubMed Web of Science ®Google Scholar
• Sorsa T, Pollesello P, Solaro RJ. The contractile apparatus as a target for drugs against heart failure: interaction of levosimendan, a calcium sensitiser, with cardiac troponin C. Mol Cell Biochem. 2004;266(1/2):87–107.
   PubMed Web of Science ®Google Scholar
• Pääkkönen K, Sorsa T, Drakenberg T, et al. Conformations of the regulatory domain of cardiac troponin C examined by residual dipolar couplings: cardiac troponin C regulatory domain conformations. Eur J Biochem. 2000;267:6665–6672.
   PubMedGoogle Scholar
• Pollesello P, Ovaska M, Kaivola J, et al. Binding of a new Ca2+ sensitizer, levosimendan, to recombinant human cardiac troponin C. A molecular modelling, fluorescence probe, and proton nuclear magnetic resonance study. J Biol Chem. 1994;269(46):28584–28590.
   PubMed Web of Science ®Google Scholar
• Sorsa T, Heikkinen S, Abbott MB, et al. Binding of levosimendan, a calcium sensitizer, to cardiac troponin C. J Biol Chem. 2001;276(12):9337–9343.
   PubMed Web of Science ®Google Scholar
• Sorsa T, Pollesello P, Rosevear PR, et al. Stereoselective binding of levosimendan to cardiac troponin C causes Ca2+-sensitization. Eur J Pharmacol. 2004;486:1–8.
   PubMed Web of Science ®Google Scholar
• Kaheinen P, Pollesello P, Levijoki J, et al. Effects of levosimendan and milrinone on oxygen consumption in isolated guinea-pig heart. J Cardiovasc Pharmacol. 2004;43(4):555–561.
   PubMed Web of Science ®Google Scholar
• Nieminen MS, Pollesello P, Vajda G, et al. Effects of levosimendan on the energy balance: preclinical and clinical evidence. J Cardiovasc Pharmacol. 2009;53(4):302–310.
   PubMed Web of Science ®Google Scholar
• Deschodt-Arsac V, Calmettes G, Raffard G, et al. Absence of mitochondrial activation during levosimendan inotropic action in perfused paced guinea pig hearts as demonstrated by modular control analysis. Am J Physiol Regul Integr Comp Physiol. 2010;299(3):R786–792.
   PubMed Web of Science ®Google Scholar
• Papp Z, Edes I, Fruhwald S, et al. Levosimendan: molecular mechanisms and clinical implications: consensus of experts on the mechanisms of action of levosimendan. Int J Cardiol. 2012;159(2):82–87.
   PubMed Web of Science ®Google Scholar
• Pagel PS, Hettrick DA, Warltier DC. Comparison of the effects of levosimendan, pimobendan, and milrinone on canine left ventricular-arterial coupling and mechanical efficiency. Basic Res Cardiol. 1996;91(4):296–307.
   PubMed Web of Science ®Google Scholar
• Kaheinen P, Pollesello P, Levijoki J, et al. Levosimendan increases diastolic coronary flow in isolated guinea-pig heart by opening ATP-sensitive potassium channels. J Cardiovasc Pharmacol. 2001;37(4):367–374.
   PubMed Web of Science ®Google Scholar
• Longrois D, Norel X, Pollesello P. Inodilator versus inotrope: do inodilators have an edge to improve outcome in patients with heart failure or cardiac dysfunction? Med Res J. 2020;5:100–109.
   Google Scholar
• Papp JG, Pollesello P, Varró AF, et al. Effect of levosimendan and milrinone on regional myocardial ischemia/reperfusion-induced arrhythmias in dogs. J Cardiovasc Pharmacol Ther. 2006;11(2):129–135.
   PubMed Web of Science ®Google Scholar
• Grossini E, Molinari C, Pollesello P, et al. Levosimendan protection against kidney ischemia/reperfusion injuries in anesthetized pigs. J Pharmacol Exp Ther. 2012;342(2):376–388.
   PubMed Web of Science ®Google Scholar
• Pollesello P, Mebazaa A. ATP-dependent potassium channels as a key target for the treatment of myocardial and vascular dysfunction. Curr Opin Crit Care. 2004;10(4):436–441.
   PubMedGoogle Scholar
• Ef DT, Genis A, Lh O, et al. A role for the RISK pathway and KATP channels in pre- and post-conditioning induced by levosimendan in the isolated guinea pig heart. Br J Pharmacol. 2008;154(1):41–50.
   PubMed Web of Science ®Google Scholar
• Grossini E, Pollesello P, Bellofatto K, et al. Protective effects elicited by levosimendan against liver ischemia/reperfusion injury in anesthetized rats. Liver Transpl. 2014;20(3):361–375.
   PubMed Web of Science ®Google Scholar
• Usta C, Puddu PE, Papalia U, et al. Comparison of the inotropic effects of levosimendan, rolipram, and dobutamine on human atrial trabeculae. J Cardiovasc Pharmacol. 2004;44(5):622–625.
   PubMed Web of Science ®Google Scholar
• Louhelainen M, Vahtola E, Kaheinen P, et al. Effects of levosimendan on cardiac remodeling and cardiomyocyte apoptosis in hypertensive Dahl/Rapp rats. Br J Pharmacol. 2007;150(7):851–861.
   PubMed Web of Science ®Google Scholar
• Grossini E, Molinari C, Caimmi PP, et al. Levosimendan induces NO production through p38 MAPK, ERK and Akt in porcine coronary endothelial cells: role for mitochondrial KATP channel. Br J Pharmacol. 2009;156(2):250–261.
   PubMed Web of Science ®Google Scholar
• Caimmi PP, Molinari C, Uberti F, et al. Intracoronary levosimendan prevents myocardial ischemic damages and activates survival signaling through ATP-sensitive potassium channel and nitric oxide. Eur J Cardiothorac Surg. 2011;39(4):e59–e67.
   PubMed Web of Science ®Google Scholar
• Grossini E, Caimmi PP, Platini F, et al. Modulation of programmed forms of cell death by intracoronary levosimendan during regional myocardial ischemia in anesthetized pigs. Cardiovasc Drugs Ther. 2010;24(1):5–15.
   PubMed Web of Science ®Google Scholar
• Grossini E, Bellofatto K, Farruggio S, et al. Levosimendan inhibits peroxidation in hepatocytes by modulating apoptosis/autophagy interplay. PLoS One. 2015;10(4):e0124742.
   PubMed Web of Science ®Google Scholar
• Grossini E, Farruggio S, Pierelli D, et al. Levosimendan improves oxidative balance in cardiogenic shock/low cardiac output patients. J Clin Med. 2020;9(2):373.
   PubMed Web of Science ®Google Scholar
• Kurdi M, Pollesello P, Booz GW. Levosimendan comes of age: 20 years of clinical use. J Cardiovasc Pharmacol. 2020;76(1):1–3.
   PubMed Web of Science ®Google Scholar
• Szilágyi S, Pollesello P, Levijoki J, et al. The effects of levosimendan and OR-1896 on isolated hearts, myocyte-sized preparations and phosphodiesterase enzymes of the guinea pig. Eur J Pharmacol. 2004;486(1):67–74.
   PubMed Web of Science ®Google Scholar
• Louhelainen M, Merasto S, Finckenberg P, et al. Effects of calcium sensitizer OR-1986 on a cardiovascular mortality and myocardial remodelling in hypertensive Dahl/Rapp rats. J Physiol Pharmacol. 2009;60(3):41–47.
   PubMed Web of Science ®Google Scholar
• Nieminen MS, Akkila J, Hasenfuss G, et al. Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure. J Am Coll Cardiol. 2000;36(6):1903–1912.
   PubMed Web of Science ®Google Scholar
• Michaels AD, McKeown B, Kostal M, et al. Effects of intravenous levosimendan on human coronary vasomotor regulation, left ventricular wall stress, and myocardial oxygen uptake. Circulation. 2005;111(12):1504–1509.
   PubMed Web of Science ®Google Scholar
• Kleber FX, Bollmann T, Borst MM, et al. Repetitive dosing of intravenous levosimendan improves pulmonary hemodynamics in patients with pulmonary hypertension: results of a pilot study. J Clin Pharmacol. 2009;49(1):109–115.
   PubMed Web of Science ®Google Scholar
• Yilmaz MB, Yalta K, Yontar C, et al. Levosimendan improves renal function in patients with acute decompensated heart failure: comparison with dobutamine. Cardiovasc Drugs Ther. 2007;21(6):431–435.
   PubMed Web of Science ®Google Scholar
• Fedele F, Bruno N, Brasolin B, et al. Levosimendan improves renal function in acute decompensated heart failure: possible underlying mechanisms. Eur J Heart Fail. 2014;16(3):281–288.
   PubMed Web of Science ®Google Scholar
• Bragadottir G, Redfors B, Ricksten SE. Effects of levosimendan on glomerular filtration rate, renal blood flow, and renal oxygenation after cardiac surgery with cardiopulmonary bypass: a randomized placebo-controlled study. Crit Care Med. 2013;41(10):2328–2335.
   PubMed Web of Science ®Google Scholar
• Onody P, Stangl R, Fulop A, et al. Levosimendan: a cardiovascular drug to prevent liver ischemia-reperfusion injury? PLoS One. 2013;8(9):e73758.
   PubMed Web of Science ®Google Scholar
• Alvarez J, Baluja A, Selas S, et al. A comparison of dobutamine and levosimendan on hepatic blood flow in patients with a low cardiac output state after cardiac surgery: a randomised controlled study. Anaesth Intensive Care. 2013;41(6):719–727.
   PubMed Web of Science ®Google Scholar
• Li H, Duan Y, Chen B, et al. New pharmacological treatments for heart failure with reduced ejection fraction (HFrEF): a Bayesian network meta-analysis. Medicine (Baltimore). 2020;99(5):e18341.
   PubMed Web of Science ®Google Scholar
• Pollesello P, Parissis J, Kivikko M, et al. Levosimendan meta-analyses: is there a pattern in the effect on mortality? Int J Cardiol. 2016;209:77–83.
   PubMed Web of Science ®Google Scholar
• Nagy L, Pollesello P, Papp Z. Inotropes and inodilators for acute heart failure: sarcomere active drugs in focus. J Cardiovasc Pharmacol. 2014;64(3):199–208.
   PubMed Web of Science ®Google Scholar
• Follath F, Cleland JG, Just H, et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet. 2002;360(9328):196–202.
   PubMed Web of Science ®Google Scholar
• Moiseyev VS, Põder P, Andrejevs N, et al. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. R randomized, placebo-controlled, double-blind study (RUSSLAN). Eur Heart J. 2002;23(18):1422–1432.
   PubMed Web of Science ®Google Scholar
• Mebazaa A, Nieminen MS, Filippatos GS, et al. Levosimendan vs. dobutamine: outcomes for acute heart failure patients on beta‑blockers in SURVIVE. Eur J Heart Fail. 2009;11(3):304–311.
   PubMed Web of Science ®Google Scholar
• Ponikowski P, Voors AA, Anker SD, et al. ESC scientific document group. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129–2200.
   PubMed Web of Science ®Google Scholar
• Rudiger A. Beta-block the septic heart. Crit Care Med. 2010;38(10 Suppl):S608–S12.
   PubMedGoogle Scholar
• Lohse MJ, Engelhardt S, Eschenhagen T. What is the role of beta-adrenergic signaling in heart failure? Circ Res. 2003;93(10):896–906.
   PubMed Web of Science ®Google Scholar
• Guarracino F, Zima E, Pollesello P, et al. Short-term treatments for acute cardiac care: inotropes and inodilators. Eur Heart J Suppl. 2020;22(SupplD):D3–D11.
   PubMedGoogle Scholar
• Harjola V-P, Giannakoulas G, Von Lewinski D, et al. Use of levosimendan in acute heart failure. Eur Heart J Suppl. 2018;20(SupplI):I2–I10.
   PubMedGoogle Scholar
• Nieminen MS, Dickstein K, Fonseca C, et al. The patient perspective: quality of life in advanced heart failure with frequent hospitalisations. Int J Cardiol. 2015;191:256–264.
   PubMed Web of Science ®Google Scholar
• Nieminen MS, Fruhwald S, Heunks LMA, et al. Levosimendan: current data, clinical use and future development. Heart Lung Vessel. 2013;5(4):227–245.
   PubMedGoogle Scholar
• Farmakis D, Alvarez J, Gal TB, et al. Levosimendan beyond inotropy and acute heart failure: evidence of pleiotropic effects on the heart and other organs: an expert panel position paper. Int J Cardiol. 2016;222:303–312.
   PubMed Web of Science ®Google Scholar
• Guarracino F, Heringlake M, Cholley B, et al. Use of levosimendan in cardiac surgery: an update after the LEVO-CTS, CHEETAH, and LICORN trials in the light of clinical practice. J Cardiovasc Pharmacol. 2018;71(1):1–9.
   PubMed Web of Science ®Google Scholar
• Van Diepen S, Mehta RH, Leimberger JD, et al. Levosimendan in patients with reduced left ventricular function undergoing isolated coronary or valve surgery. J Thorac Cardiovasc Surg. 2020;159(6):2302–2309.e6.
   PubMed Web of Science ®Google Scholar
• Tritapepe L, De Santis V, Vitale D, et al. Levosimendan pre-treatment improves outcomes in patients undergoing coronary artery bypass graft surgery. Br J Anaesth. 2009;102(2):198–204.
   PubMed Web of Science ®Google Scholar
• Tritapepe L, De Santis V, Vitale D, et al. Preconditioning effects of levosimendan in coronary artery bypass grafting—a pilot study. Br J Anaesth. 2006;96(6):694–700.
   PubMed Web of Science ®Google Scholar
• Sanfilippo F, Knight JB, Scolletta S, et al. Levosimendan for patients with severely reduced left ventricular systolic function and/or low cardiac output syndrome undergoing cardiac surgery: a systematic review and meta-analysis. Crit Care. 2017;21(1):252.
   PubMed Web of Science ®Google Scholar
• Weber C, Esser M, Eghbalzadeh K, et al. Levosimendan reduces mortality and low cardiac output syndrome in cardiac surgery. Thorac Cardiovasc Surg. 2020;68(5):401–409.
   PubMedGoogle Scholar
• Toller W, Heringlake M, Guarracino F, et al. Preoperative and perioperative use of levosimendan in cardiac surgery: european expert opinion. Int J Cardiol. 2015;184:323–336.
   PubMed Web of Science ®Google Scholar
• Zochios V, Parhar K, Tunnicliffe W, et al. The right ventricle in ARDS. Chest. 2017;152(1):181–193.
   PubMed Web of Science ®Google Scholar
• Denault AY, Bussières JS, Arellano R, et al. A multicentre randomized-controlled trial of inhaled milrinone in high-risk cardiac surgical patients. Can J Anesth. 2016;63(10):1140–1153.
   PubMed Web of Science ®Google Scholar
• Slawsky MT, Colucci WS, Gottlieb SS, et al. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Study Investigators. Circulation. 2000;102(18):2222–2227.
   PubMedGoogle Scholar
• Szabó G, Soós P, Bährle S, et al. Adaptation of the right ventricle to an increased afterload in the chronically volume overloaded heart. Ann Thorac Surg. 2006;82(3):989–995.
   PubMed Web of Science ®Google Scholar
• Hansen MS, Andersen A, Tolbod LP, et al. Levosimendan improves cardiac function and myocardial efficiency in rats with right ventricular failure. Pulm Circ. 2007;8:2045893217743122.
   Google Scholar
• Qiu J, Jia L, Hao Y, et al. Efficacy and safety of levosimendan in patients with acute right heart failure: a meta-analysis. Life Sci. 2017;184:30–36.
   PubMed Web of Science ®Google Scholar
• Hansen MS, Andersen A, Holmboe S, et al. Levosimendan prevents and reverts right ventricular failure in experimental pulmonary arterial hypertension. J Cardiovasc Pharmacol. 2017;70(4):232–238.
   PubMed Web of Science ®Google Scholar
• Hemodynamic evaluation of levosimendan in patients with PH-HFpEF (HELP). Bethesda (MD): US national library of medicine. [cited 2021 Mar 23]. Available from: https://clinicaltrials.gov/ct2/show/NCT03541603?term=levosimendan&cond=Pulmonary±Hypertension&draw=2&rank=2.
   Google Scholar
• Borlaug B Levosimendan improves hemodynamics and submaximal exercise capacity in PH-HFpEF: primary results from the HELP-PH-HFpEF multicenter randomized controlled trial. https://hfsa.org/hfsa-announces-late-breaking-clinical-trials-sessions-hfsa-virtual-asm-2020 Last accessed 2020 Oct 5
   Google Scholar
• Tenax therapeutics reports positive results from phase 2 trial of levosimendan in patients with pulmonary hypertension and heart failure with preserved ejection fraction (PH-HFpEF). Yahoo! Finance [Internet]. Los Angeles (CA): Verizon Media Inc. [ cited 2020 Sept 22]. Available from: https://finance.yahoo.com/news/tenax-therapeutics-reports-positive-results-113000096.html?_guc_consent_skip=1600750580. Last accessed 2020 Oct 5.
   Google Scholar
• Herpain A, Bouchez S, Girardis M, et al. Use of levosimendan in intensive care unit settings: an opinion paper. J Cardiovasc Pharmacol. 2019;73(1): 3–14.
   PubMed Web of Science ®Google Scholar
• Gordon AC, Perkins GD, Singer M, et al. Levosimendan for the prevention of acute organ dysfunction in sepsis. N Engl J Med. 2016;375(17):1638–1648.
   PubMed Web of Science ®Google Scholar
• Groesdonk HH, Sander M, Heringlake M, et al. Levosimendan in sepsis. N Engl J Med. 2017;376:798.
   PubMedGoogle Scholar
• Cappellini I, Melai A, Zamidei L, et al. Levosimendan and Global Longitudinal Strain Assessment in Sepsis (GLASSES 1): a study protocol for an observational study. BMJ Open. 2020;10(9):e037118.
   Web of Science ®Google Scholar
• Rhodes A, Evans LE, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Crit Care Med. 2017;45:486–552.
   PubMed Web of Science ®Google Scholar
• Suzuki T, Suzuki Y, Okuda J, et al. Sepsis-induced cardiac dysfunction and β-adrenergic blockade therapy for sepsis. J Intensive Care. 2017;5(1):22.
   PubMedGoogle Scholar
• Standl T, Annecke T, Cascorbi I, et al. The nomenclature, definition and distinction of types of shock. Dtsch Arztebl Int. 2018;115(45):757–768.
   PubMed Web of Science ®Google Scholar
• Steg PG, James SK, Atar D, et al. Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2012;33:2569–2619.
   PubMed Web of Science ®Google Scholar
• Van Diepen S, Baran DA, Mebazaa A. What is the role of medical therapy in cardiogenic shock in the era of mechanical circulatory support? Can J Cardiol. 2020;36(2):151–153.
   PubMed Web of Science ®Google Scholar
• Thiele H, Ohman EM, De Waha-thiele S, et al. Management of cardiogenic shock complicating myocardial infarction: an update 2019. Eur Heart J. 2019;40(32):2671–2683.
   PubMed Web of Science ®Google Scholar
• García-González MJ, Domínguez-Rodríguez A, Ferrer-Hita JJ, et al. Cardiogenic shock after primary percutaneous coronary intervention: effects of levosimendan compared with dobutamine on haemodynamics. Eur J Heart Fail. 2006;8(7):723–728.
   PubMed Web of Science ®Google Scholar
• Fuhrmann JT, Schmeisser A, Schulze MR, et al. Levosimendan is superior to enoximone in refractory cardiogenic shock complicating acute myocardial infarction. Crit Care Med. 2008;36(8):2257–2266.
   PubMed Web of Science ®Google Scholar
• Fang M, Cao H, Wang Z. Levosimendan in patients with cardiogenic shock complicating myocardial infarction: a meta-analysis. Med Intensiva. 2018;42(7):409–415.
   PubMed Web of Science ®Google Scholar
• Schumann J, Henrich EC, Strobl H, et al. Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome. Cochrane Database Syst Rev. 2018;1:CD009669.
   PubMedGoogle Scholar
• Sangalli F, Bellani G, Affronti A, et al. Levosimendan to facilitate weaning from cardiorespiratory support in critically ill patients: current evidence and future directions. Minerva Anestesiol. 2020;86(6):645–651.
   PubMed Web of Science ®Google Scholar
• Sterba M, Banerjee A, Mudaliar Y. Prospective observational study of levosimendan and weaning of difficult-to-wean ventilator dependent intensive care patients. Crit Care Resusc. 2008;10(3):182–186.
   PubMedGoogle Scholar
• Roesthuis L, Van Der Hoeven H, Sinderby C, et al. Effects of levosimendan on respiratory muscle function in patients weaning from mechanical ventilation. Intensive Care Med. 2019;45(10):1372–1381.
   PubMed Web of Science ®Google Scholar
• Affronti A, Di Bella I, Carino D, et al. Levosimendan may improve weaning outcomes in venoarterial ECMO patients. Asaio J. 2013;59(6):554–557.
   PubMed Web of Science ®Google Scholar
• Distelmaier K, Roth C, Schrutka L, et al. Beneficial effects of levosimendan on survival in patients undergoing extracorporeal membrane oxygenation after cardiovascular surgery. Br J Anaesth. 2016;117(1):52–58.
   PubMed Web of Science ®Google Scholar
• Jacky A, Rudiger A, Krüger B, et al. Comparison of levosimendan and milrinone for ECLS weaning in patients after cardiac surgery—A retrospective before and after study. J Cardiothorac Vasc Anesth. 2018;32(5):2112–2119.
   PubMed Web of Science ®Google Scholar
• Pan KC, Shankar S, Millar J, et al. Role of levosimendan in weaning children requiring veno-arterial extracorporeal membrane oxygenation after cardiac surgery. Eur J Cardiothor Surg. 2021;59(1):262-268.
   PubMed Web of Science ®Google Scholar
• Lyon A, Bossone E, Schneider B, et al. Current state of knowledge on takotsubo syndrome: a position statement from the taskforce on takotsubo syndrome of the heart failure association of the european society of cardiology. Eur J Heart Fail. 2016;18(1):8–27.
   PubMed Web of Science ®Google Scholar
• De Santis V, Vitale D, Tritapepe L, et al. Use of levosimendan for cardiogenic shock in a patient with the apical ballooning syndrome. Ann Intern Med. 2008;149(5):365–367.
   PubMed Web of Science ®Google Scholar
• Santoro F, Ieva R, Ferraretti A, et al. Safety and feasibility of levosimendan administration in takotsubo cardiomyopathy: a case series. Cardiovasc Ther. 2013;31(6):e133–e137.
   PubMed Web of Science ®Google Scholar
• Yaman M, Arslan U, Kaya A, et al. Levosimendan accelerates recovery in patients with takotsubo cardiomyopathy. Cardiol J. 2016;23(6):610–615.
   PubMed Web of Science ®Google Scholar
• Santoro F, Mallardi A, Leopizzi A, et al. Current knowledge and future challenges in Takotsubo syndrome: part 2-Treatment and prognosis. J Clin Med. 2021;10(3):468.
   PubMed Web of Science ®Google Scholar
• Tavazzi G, Mojoli F, Iotti GA, et al. Does levosimendan have room in Takotsubo syndrome? JACC Heart Fail. 2019;7(2):174.
   PubMed Web of Science ®Google Scholar
• Yilmaz MB, Grossini E, Silva Cardoso JC, et al. Renal effects of levosimendan: a consensus report. Cardiovasc Drugs Ther. 2013;27(6):581–590.
   PubMed Web of Science ®Google Scholar
• Lannemyr L, Ricksten SE, Rundqvist B, et al. Differential effects of levosimendan and dobutamine on glomerular filtration rate in patients with heart failure and renal impairment: a randomized double-blind controlled trial. J Am Heart Assoc. 2018;7(16): e008455.
   PubMed Web of Science ®Google Scholar
• Lannemyr L, Bragadottir G, Redfors B, et al. Effects of milrinone on renal perfusion, filtration and oxygenation in patients with acute heart failure and low cardiac output early after cardiac surgery. J Crit Care. 2020;57:225–230.
   PubMed Web of Science ®Google Scholar
• Chen W-C, Lin M-H, Chen C-L, et al. Comprehensive comparisons among inotropic agents on mortality and risk of renal dysfunction in patients who underwent cardiac surgery: a network meta-analysis of randomized controlled trials. J Clin Med. 2021;10(5):1032.
   PubMed Web of Science ®Google Scholar
• Guerrero-Orriach JL, Malo-Manso A, Ramirez-Aliaga M, et al. Renal and neurologic benefit of levosimendan vs dobutamine in patients with low cardiac output syndrome after cardiac surgery: clinical trial FIM-BGC-2014-01. Front Pharmacol. 2020;11:1331.
   PubMedGoogle Scholar
• Packer M, Colucci W, Fisher L, et al. Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure. JACC Heart Fail. 2013;1(2):103–111.
   PubMed Web of Science ®Google Scholar
• Gong B, Li Z, Yat Wong PC. Levosimendan treatment for heart failure: a systematic review and meta-analysis. J Cardiothorac Vasc Anesth. 2015;29(6):1415–1425.
   PubMed Web of Science ®Google Scholar
• Landoni G, Biondi-Zoccai G, Greco M, et al. Effects of levosimendan on mortality and hospitalization. A meta-analysis of randomized controlled studies. Crit Care Med. 2012;40(2):634–646.
   PubMed Web of Science ®Google Scholar
• Farmakis D, Agostoni P, Baholli L, et al. A pragmatic approach to the use of inotropes for the management of acute and advanced heart failure: an expert panel consensus. Int J Cardiol. 2019;297:83–90.
   PubMed Web of Science ®Google Scholar
• Bouchez S, Fedele F, Giannakoulas G, et al. Levosimendan in acute and advanced heart failure: an expert perspective on posology and therapeutic application. Cardiovasc Drugs Ther. 2018;32(6):617–624.
   PubMed Web of Science ®Google Scholar
• Pollesello P, Ben Gal T, Bettex D, et al. Short-term therapies for treatment of acute and advanced heart failure: why so few drugs available in clinical use, why even fewer in the pipeline? J Clin Med. 2019;8(11):e1834.
   PubMed Web of Science ®Google Scholar
• Papp Z, Agostoni P, Alvarez J, et al. Levosimendan efficacy and safety: 20 years of SIMDAX in clinical use. J Cardiovasc Pharmacol. 2020;76(1): 4–22.
   PubMed Web of Science ®Google Scholar
• Papp Z, Agostoni P, Alvarez J, et al. Levosimendan efficacy and safety: 20 years of SIMDAX in clinical use. Card Fail Rev. 2020;6:e19.
   PubMedGoogle Scholar
• Ghadri J-R, Wittstein IS, Prasad A, et al. International expert consensus document on Takotsubo syndrome (part ii): diagnostic workup, outcome, and management. Eur Heart J. 2018;39(22):2047–2062.
   PubMed Web of Science ®Google Scholar
• Landoni G, Lomivorotov V, Silvetti S, et al. Nonsurgical strategies to reduce mortality in patients undergoing cardiac surgery: an updated consensus process. J Cardiothorac Vasc Anesth. 2018;32(1):225–235.
   PubMed Web of Science ®Google Scholar
• Mebazaa A, Nieminen MS, Packer M, et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized Trial. JAMA. 2007;297(17):1883–1891.
   PubMed Web of Science ®Google Scholar